Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
- PMID: 27401154
- DOI: 10.1007/s11060-016-2201-2
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
Abstract
The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.
Keywords: 1p/19q; Glioma; IDH; Magnetic resonance imaging; Surgery; WHO grade III.
Similar articles
-
18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3. Ann Nucl Med. 2019. PMID: 30607877
-
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284. World J Surg Oncol. 2013. PMID: 24160898 Free PMC article.
-
Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.Brain Tumor Pathol. 2018 Jul;35(3):148-158. doi: 10.1007/s10014-018-0321-4. Epub 2018 Jun 19. Brain Tumor Pathol. 2018. PMID: 29922974
-
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.Neurosurg Focus. 2019 Dec 1;47(6):E13. doi: 10.3171/2019.9.FOCUS19660. Neurosurg Focus. 2019. PMID: 31786548
-
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv100-8. doi: 10.1093/neuonc/nos206. Neuro Oncol. 2012. PMID: 23095825 Free PMC article. Review.
Cited by
-
Diagnostic accuracy of a machine learning-based radiomics approach of MR in predicting IDH mutations in glioma patients: a systematic review and meta-analysis.Front Oncol. 2024 Jul 30;14:1409760. doi: 10.3389/fonc.2024.1409760. eCollection 2024. Front Oncol. 2024. PMID: 39139289 Free PMC article.
-
Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.BMC Cancer. 2024 Feb 16;24(1):222. doi: 10.1186/s12885-024-11970-y. BMC Cancer. 2024. PMID: 38365669 Free PMC article.
-
The sinuous, wave-like intratumoral-wall sign is a sensitive and specific radiological biomarker for oligodendrogliomas.Eur Radiol. 2023 Jun;33(6):4440-4452. doi: 10.1007/s00330-022-09314-0. Epub 2022 Dec 15. Eur Radiol. 2023. PMID: 36520179
-
The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study.J Neurooncol. 2018 Dec;140(3):591-603. doi: 10.1007/s11060-018-2985-3. Epub 2018 Sep 11. J Neurooncol. 2018. PMID: 30206763
-
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Cancer Cell. 2018 Aug 13;34(2):186-195. doi: 10.1016/j.ccell.2018.04.011. Epub 2018 May 24. Cancer Cell. 2018. PMID: 29805076 Free PMC article. Review.
References
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous